Arrowhead Pharmaceuticals, Inc. Earnings

Arrowhead Pharmaceuticals, Inc.’s revenue jumped +Inf% since last year same period to $27.77Mn in the Q2 2025. On a quarterly growth basis, Arrowhead Pharmaceuticals, Inc. has generated -94.88% fall in its revenue since last 3-months.

Arrowhead Pharmaceuticals, Inc.’s net profit fell -2.6% since last year same period to $-175.24Mn in the Q2 2025. On a quarterly growth basis, Arrowhead Pharmaceuticals, Inc. has generated -147.31% fall in its net profits since last 3-months.

Arrowhead Pharmaceuticals, Inc.’s net profit margin jumped NaN% since last year same period to -631.11% in the Q2 2025. On a quarterly growth basis, Arrowhead Pharmaceuticals, Inc. has generated -1024.59% fall in its net profit margins since last 3-months.

Arrowhead Pharmaceuticals, Inc.’s earning per share (EPS) estimates for the current quarter stand at -0.18 - a 79.01% jump from last quarter’s estimates.

Arrowhead Pharmaceuticals, Inc.’s earning per share (EPS) estimates for the current year stand at -0.18.

Arrowhead Pharmaceuticals, Inc.’s earning per share (EPS) jumped 100% since last year same period to 0 in the Q3 2025. This indicates that the Arrowhead Pharmaceuticals, Inc. has generated 100% annual rate of jump in its earning per share (EPS) in the last 4 quarters.